国民彩票

 

Dal PhD candidate among elite young scientists nominated to attend Lindau Nobel Laureate meeting

- December 11, 2017

PhD candidate Simon Gebremeskel. (Jollymore photos)
PhD candidate Simon Gebremeskel. (Jollymore photos)

Award-winning 国民彩票 PhD student Simon Gebremeskel is a pioneer in discovering how the immune system can fight cancer.

鈥淭he more we know, the more we realize we don't know. We're only starting to scratch the surface,鈥 says says Gebremeskel who, as top-prize winner at this year鈥檚 Canadian Student Health Research Forum, has earned himself a coveted nomination to attend the Lindau Nobel Laureate Meeting in Germany in 2018.

Cancer-killing combo


Gebremeskel is working with Dr. Brent Johnston in 国民彩票 Medical School鈥檚 Department of Microbiology & Immunology to develop a cancer treatment that kills cancer cells by both activating the immune system and introducing viruses that kill cancer cells. This novel combination strategy 鈥 of immunotherapy plus oncolytic viruses 鈥 could be available within a few years.


Simon Gebremeskel with Dr. Brent Johnston.

In fact, Gebremeskel predicts people with cancer will be treated entirely differently within 鈥渢he next decade or so,鈥 once the costs of groundbreaking new treatments come down.

The beauty of cancer immunotherapy is that side effects are not as severe as those in surgery, chemotherapy and radiation. And, there is evidence the immune system 鈥渞emembers,鈥 so it will fight off new attacks by a returning cancer.

It's a cops and robbers story with scientists racing towards a cure while devious cancer cells try to outwit the immune system.

Cancer as immune deficiency disease


鈥淲hat's becoming clear in the field of cancer therapy is the majority of cancer patients should be looked at as patients who have immune deficiency,鈥 says the Kenyan-born scientist, who did his undergraduate degree at Queen's University. 鈥淣ormal cells in our body become transformed quite frequently into pre-cancerous or early-stage cancer cells. Evidence suggests the immune system is able to recognize these changed cells and clear them off.鈥

As Gebremeskel explains, cancer erupts for two reasons: 鈥淭he immune system fails to recognize the changed cell, which is now cancerous, and the new cancer cell turns off the immune system, essentially enabling it to proliferate without any checks and balances.鈥

The two-pronged approach that Gebremeskel and the team in Dr. Johnston鈥檚 lab have developed helps the immune system fight cancer in two ways. First, they use viruses to infect and kill cancer cells in a way that makes any remaining cancer cells visible to the immune system. 鈥淪econd, we use compounds that activate the immune system to help it overcome any attempts to shut it down,鈥 he says. 鈥淭he challenge will be convincing clinicians that you get a better response when you combine these two approaches.鈥

The Johnston lab is working with melanomas and breast, ovarian and pancreatic cancers, investigating when to introduce each approach.

鈥淲e know giving the virus first works, but is that the best outcome? If we flip the order, would we get an even better therapeutic be